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A B S T R A C T   
The pig has been increasingly used as a reliable preclinical model for assessing and predicting the in vivo 
bioavailability of different formulation strategies. Nevertheless, differences in the composition between porcine 
and human intestinal fluids, may impact on the solubility and dissolution behaviour of drugs, in particular BCS 
II/IV drugs. Recently, a porcine fasted simulated intestinal fluid (FaSSIFp) was developed to mimic the 
composition in the lumen of landrace pigs under fasted state conditions. In this work, we present the utilization 
of FaSSIFp to compare solubility against human FaSSIF & FeSSIF and further combine species specific in vitro 
testing with in silico predictive modelling. Venetoclax was chosen as a model drug, representing a BCS class IV 
drug, with a reported clinically significant positive food effect, where bioavailability is increased up to 
approximately five-fold when administered with a high-fat meal. Biorelevant species specific in vitro testing was a 
promising tool for integrating in vitro data into in silico models, using FaSSIFp resulted in reliable predictions of 
the plasma concentration profile in fasted pigs, based on a porcine physiologically based absorption model. The 
porcine physiologically based absorption model was used to prospectively simulate the impact of food on the 
bioavailability of venetoclax. The use of luminal solubility estimates in combination with dissolution data for 
venetoclax, measured in species specific simulated fluids, correctly predict the observed pig plasma concentra-
tion profile and food effect. Overall, integrating species specific in vitro – in silico models led to accurate pre-
diction of in vivo absorption of venetoclax in a preclinical stage, which can support guidance in early decisions of 
drug product development. In addition, the study further demonstrated the utility of the pig model to predict the 
food effects of venetoclax in humans.   
1. Introduction 
Preclinical bioavailability predictions of new drug candidates 
require a thorough understanding of factors influencing drug absorp-
tion. A key factor in dosage form development is the biopharmaceutical 
understanding of potential food effects of a drug product, taking into 
consideration not only the drug substance, but also the formulation 
strategy (Koziolek et al., 2019). It is crucial to assess the potential impact 
of food on oral pharmacokinetics early in formulation development to 
allow optimization of formulation design and prevent costly reformu-
lation later in the development process (O’Shea et al., 2018). In the last 
decade, physiologically based pharmacokinetic (PBPK) modelling has 
been increasingly used to forecast formulation and food effects on in vivo 
drug plasma concentrations. The use of PBPK models during formulation 
development is an excellent tool for the prediction of preclinical and 
clinical pharmacokinetics (PK) using physiochemical and in vitro mea-
surements. A key aspect for accurate predictions using PBPK models is 
the ability to combine accurate in vitro estimates of in vivo drug related 
parameters, such as luminal solubility and tissue permeability, and 
reliable physiological measurements, including gastrointestinal transit 
times, luminal volume and fluid pH (Henze et al., 2018b). Therefore, 
accurate estimation of drug solubility in the gastrointestinal tract is 
considered fundamental for better understanding of absorption limita-
tions, in particular for BCS class II and IV compounds, where poor 
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solubility is likely to be a rate limiting step in absorption (Walsh et al., 
2017). Physiochemical characterisation of human intestinal fluids is 
well described (Augustijns et al., 2014) and the development of fluids to 
simulate either gastric (fasted state simulated gastric fluid, FaSSGF) or 
intestinal (fasted state simulated intestinal fluid, FaSSIF) contents is well 
documented (Jantratid et al., 2008; Vertzoni et al., 2005). These 
established biorelevant media, are routinely used for dissolution and 
solubility studies during drug development (Bergstrom et al., 2014; 
Klein, 2010). While these media have proved suitable for humans, 
FaSSIF cannot be used for the simulation of intestinal contents of pre-
clinical models, due to key differences in animal and human intestinal 
fluid characteristics (Arndt et al., 2013; Henze et al., 2020; Sjogren et al., 
2014). Therefore, species specific intestinal media have been developed 
to simulate preclinical animal gastrointestinal conditions, with the aim 
to improve predictions and interpretation of preclinical results. Arndt et 
al. developed different canine biorelevant media simulating fasted 
gastric and intestinal conditions in dogs (Arndt et al., 2013). More 
recently a porcine biorelevant medium was established, based on fasted 
intestinal content characteristics of pigs (Henze et al., 2020). Both media 
are specially adapted to reflect species specific properties in the 
gastrointestinal tract, such as pH, buffer capacity, osmolality, surface 
tension and bile and phospholipid concentrations. Combining species 
specific in vitro testing with in silico modelling, may give early insights in 
preclinical development of drug behaviour after oral administration and 
can be employed to allow drug formulation characterisation in advance 
of in vivo testing (Arndt et al., 2013). To date, only the canine media 
have been used to explore the predictability of plasma concentration 
profiles in dogs, combining the species specific in vitro testing with in 
silico modelling (Walsh et al., 2017). The observed data indicated that 
the solubility in canine biorelevant media was significantly higher 
compared to human FaSSIF, in particular for weak acids. Using a model 
drug (‘compound free acid 6’), the pharmacokinetics of amorphous and 
crystalline formulations in beagle dogs was predicted using in silico 
modelling. The simulations showed that using human FaSSIF the 
observed drug plasma concentrations were under predicted for both 
formulations, while the canine biorelevant media clearly improved the 
predictions. 
Recently, we have developed a protocol for predicting food effect 
using a pig model, utilizing a standard high-caloric, high-fat meal to 
mimic postprandial conditions present in human food effect studies 
(FDA, 2002; Henze et al., 2019). Given the dual priorities in early drug 
development phases of developing bioenabling formulations to address 
solubility limitations and assessing the impact of food on bioavailability 
as early as possible, is it logical that these decisions are made in parallel, 
rather than in sequence. Hence, reliable preclinical models are impor-
tant to assess the interplay of food and drug formulations, as well as 
providing insights to the optimal formulation approach for poorly sol-
uble drugs. 
The main objective of this study, was to assess the suitability of 
species specific in vitro solubility and dissolution data to predict the drug 
absorption profile of venetoclax in pigs. A secondary aim of this study 
was to assess the reliability of the combined in vitro-in silico porcine 
model to predict the post-prandial drug absorption profile by compari-
son to the in vivo absorption observed in fed state in pigs. Venetoclax, a 
BCS Class IV drug, was chosen as a model drug on the basis of its pro-
found food dependent bioavailability reported in humans (Salem et al., 
2016). These properties lead to challenges during formulation devel-
opment and prediction of the absorption behaviour under postprandial 
conditions. Therefore, this study provides new insights on the use of in 
vitro and in silico tools in preclinical development using a model drug 
with poor biopharmaceutical properties to predict food effects in 
humans. 
2. Materials and methods 
2.1. Chemicals and materials 
Venetoclax was purchased from Kemprotec Ltd. (UK). Venclyxto® 
100 mg tablets were commercially sourced from local pharmacies. Li-
poid E PC S (Phosphatidylcholine) was obtained from Lipoid GmbH 
(Germany), sodium taurodeoxycholate; sodium hydroxide (NaOH) pel-
lets; chloroform; sodium chloride (NaCl); sodium dihydrogen phosphate 
monohydrate; sodium oleate were purchased from Sigma Aldrich 
(Ireland) and sodium taurocholate was ordered from Thermo Scientific 
Ltd., Alfa Aesar (UK). Fasted state simulating intestinal fluid (FaSSIF) 
and fed state simulating intestinal fluid (FeSSIF) powder was kindly 
donated by biorelevant.com (UK). All food components used in pre-
paring FDA standard breakfast were purchased commercially. Water 
was produced using a MilliQ system (Merck KGaA, Germany). All other 
chemicals and solvents were of analytical grade or HPLC grade, 
respectively, and were purchased from Sigma–Aldrich (Ireland) and 
used as received. 
2.2. Biorelevant solubility and dissolution 
Solubility was measured ex vivo in pig intestinal fluids (PIF). Pig 
intestinal contents have been collected in previous studies and upon 
collection they were frozen (-80◦C) until further analysis (Henze et al., 
2019). On the day of the solubility experiment all samples were brought 
to room temperature. Fluid samples were pooled by taking 3 mL from 
each sample (total 6 samples) to create the PIF samples. FaSSIF and 
FeSSIF were prepared as outlined in the instructions by biorelevant.com. 
FeSSIF was used directly, whereas FaSSIF was left at room temperature 
for 2 hours prior to the solubility studies. Porcine Fasted State Simulated 
Intestinal Fluid (FaSSIFp) was prepared as recently described (Henze 
et al., 2020). The composition of FaSSIFp is summarized in Table 1. 
Solubility studies were carried out by the addition of excess venetoclax 
to biorelevant media using a shake flask method (200 shakes/min) with 
Table 1 
Composition and physiochemical properties of the medium to simulate the porcine fasted state small intestine – Fasted State Simulated Intestinal Fluid porcine 
(FaSSIFp)  
Composition FaSSIFp mM 
Buffer Sodium dihydrogen phosphate monohydrate 
Sodium hydroxide 








Phospholipids Lecithin 0.20 
Fatty acid Sodium oleate 2.82 
pH 7.0  
Buffer capacity [mmol l-1∆pH-1] 19.4  
Osmolality [mOsm kg-1] 387   
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a shake time of 24 h at 37◦C. Samples were taken at 3 h, 6 h and 24 h and 
added to 1.5 mL centrifuge tubes. Samples were centrifuged at 11,000 
rpm for 10 min (Mikro 200 R, Hettich GmbH, Germany). The superna-
tant was transferred to a new tube and 2 mL of acetonitrile was added 
(PIF solubility) and centrifuged again under the same conditions. The 
resultant supernatant was analysed using HPLC after appropriate dilu-
tion with mobile phase. All samples were run in triplicate. 
Biorelevant dissolution was carried out using the dissolution appa-
ratus USP II (Erweka DT600, Erweka GmbH, Germany) at 75 rpm. Tests 
were performed using 500 mL of FaSSIF, FeSSIF or porcine biorelevant 
media at 37 ± 0.5 ◦C. Experiments were performed in triplicate. Ven-
etoclax tablets (Venclyxto® 100 mg tablets) were placed in the disso-
lution medium, and samples of 4 mL were withdrawn at 5, 10, 15, 20, 
30, 45, 60, 90, 120 and 180 min, immediately followed by addition of an 
equal volume of fresh, pre-warmed medium. The withdrawn samples 
were filtered through a 0.45 μm cellulose acetate membrane filter (VWR 
International), discarding the first 2 mL. The resultant filtrate was 
visually assessed as being clear and free from particles. 100 μL of sample 
was immediately diluted with 900 μL of mobile phase and analysed 
using HPLC. 
2.3. Quantitative analysis of venetoclax solubility and dissolution samples 
The concentrations of venetoclax from solubility/ dissolution ex-
periments were determined using a validated HPLC-UV method (Koehl 
et al., 2020). In brief, the limit of detection (LOD) was determined to be 
19.52 ng/mL and the limit of quantification (LOQ) was 65.08 ng/mL The 
variability around the LOQ is 5.2 %. The reproducibility of the method 
at 500 ng/mL, 1250 ng/mL, 2000 ng/mL, 3000 ng/mL, 4000 ng/mL, 
9500 ng/mL and 12500 ng/mL, expressed as the inter-day coefficient of 
variation was 5.19 %, 3.66 %, 4.96 %, 4.73 %, 4.18 %, 4.00 % and 3.67 
% respectively. Linearity was demonstrated between the range of 50 
ng/mL to 12.5 μL/mL. Samples were analysed using an Agilent 1200 
series HPLC system comprised a binary pump, degasser, column oven, 
autosampler and variable wavelength detector. Data analysis was car-
ried out with EZChrom Elite version 3.2. Venetoclax was separated with 
a Zorbax Eclipse Plus-C18 column (5 μm, 4.6 mm x 150 mm) including a 
Zorbax Eclipse Plus-C18 guard column (5 μm, 4.6 mm x 12.5 mm) at 40 
◦C. The mobile phase consisted of acetonitrile with 0.5 % TFA and Water 
with 0.5 % TFA (53:47) and was used at a flow rate of 1 mL/min. 20 μL 
samples were injected and the detection wavelength was 290 nm. The 
limit of detection (LOD) was 20 ng/mL and the limit of quantification 
(LOQ) 65 ng/mL determined using the standard error of y-intercept 
according to ICH Q2 (ICH, 2005). 
2.4. In vivo oral bioavailability study in pigs 
The study was carried out under the licence issued by the Health 
Products Regulatory Authority (HPRA), Ireland, as directed by the 
Cruelty to Animals Act, Ireland and EU Statutory Instruments (Licence 
number AE19130/P058). Local University ethical committee approval 
was obtained. The study was a non-randomised, three-way crossover 
design (I. fasted state, II. Fed state, III. intravenous administration) 
where five male landrace pigs (15–17 kg) were sourced locally and 
housed individually at the University’s Biological Services Unit. 
Throughout the study pigs were fed approximately 175 g of standard 
weanling pig pellet feed twice daily. In the fasted leg of the study the 
final feed of 175 g was given 24 h prior to dosing. As part of the study 
design any remaining food was removed 16 h before dosing, however, 
no food remained at this point in any of the groups. In the fed state pigs 
were fed a half portion of a standard high-caloric, high-fat FDA breakfast 
(444 kcal, 315 g, one slice of bacon, one slice buttered toast, one fried 
egg, 118 mL whole milk, 60 g hashed brown potatoes). The mass of FDA 
breakfast fed equated to approximately 18 – 20 g/kg of body weight. 
On day one, an indwelling intravenous catheter was inserted into the 
jugular vein via an ear vein under general anaesthesia, as previously 
described (Framstad T., 2000; Pairis-Garcia et al., 2014; Swindle, 2010, 
2016; Swindle and Smith, 2013a). Following an overnight fast on day 
three, oral formulation of 100 mg venetoclax (Venclyxto®) was 
administered with the aid of a dosing device, after which the pigs 
received 50 mL of water via a syringe. Under fed state conditions, pigs 
received the meal 30 minutes prior to oral dosing. After dosing, pigs 
were returned to their pens. Blood samples (4 mL) were collected at time 
zero (pre-dosing) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 24 h 
post-dosing. Water was restricted for 3 h post dosing and all pigs were 
fed 175g of pig feed 8 h post dosing. All blood samples were collected in 
heparinised tubes (Sarstedt, Germany) and immediately centrifuged at 
3220 g for 5 min at 4 ◦C (Eppendorf 5810r swinging bucket rotor 
centrifuge, Eppendorf AG, Hamburg, Germany). Plasma was collected 
and stored at − 80 ◦C. A six-day washout period was used between each 
phases. All animals remained in good health throughout the study. 
The intravenous venetoclax formulation contained 25 % Tween 80 in 
water for injection, which was administered over 5 minutes, blood 
samples were collected at 5, 15, 30, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 
24 h, centrifuged and collected plasma was stored at − 80 ◦C. 
2.5. Bioanalysis of venetoclax 
The plasma concentrations of venetoclax were determined by 
reversed phase HPLC. The Agilent 1260 series system comprised a bi-
nary pump, degasser, temperature controlled autosampler, column oven 
and diode array detector. The system was controlled, and the data 
analysed with EZChrom Elite version 3.3.2. A Zorbax Eclipse Plus-C18 
column (5 μm, 4.6 mm x 150 mm) with a Zorbax Eclipse Plus-C18 
guard column (5 μm, 4.6 mm x 12.5 mm) was used for the separation 
of venetoclax. The mobile phase consisted of water and acetonitrile with 
0.5 % TFA (47:53 v/v) and was used at a flow rate of 1.0 mL/min. The 
sample and column temperature were set at 5 ◦C and 40 ◦C, respectively, 
and the detection wavelength was set to 250, 290 and 316 nm. Ven-
etoclax was extracted from the plasma samples by liquid-liquid extrac-
tion. To 500 μL of the plasma 50 μL vemurafenib (internal standard 
dissolved in acetonitrile) and 450 μL of acetonitrile was added. The 
mixture was mixed thoroughly, and 1 mL of ethyl acetate was added 
followed by mixing for 15 sec. The mixture was centrifuged at 25 ◦C, 
11,500 g for 5 minutes. 1.5 mL of the supernatant was recovered and 
transferred to a new tube. The supernatant was dried at 60 ◦C under a 
nitrogen stream. To the remaining plasma sample 1 mL of ethyl acetate 
was added and the mixture was thoroughly mixed and centrifuged using 
the same condition as above. 1 mL supernatant was recovered and 
transferred to the same tube as above. After drying of the supernatant, 
the residues were reconstituted in 100 μL mobile phase (excluding TFA) 
followed by centrifugation at 25 ◦C, 11,500 g for 5 minutes. 50 μL of the 
supernatant was injected for analysis. The LOD and LOQ in plasma by 
this method was 6 ng/mL and 20 ng/mL, respectively, determined using 
the standard error of y-intercept according to ICH Q2 (ICH, 2005). 
Linearity was confirmed between 25 ng/ml and 2.5 μg/ml. 
2.6. Pharmacokinetic analysis 
Exposure after oral administration was estimated by calculating the 
area under the plasma concentration curve (AUC) for 8 h and 24 h post 
dosing for venetoclax by using PKPlus (Gastroplus.9.5). AUC and mean 
residence time (MRT) were determined from non-compartmental anal-
ysis. The peak plasma concentrations (Cmax) and the time for their 
occurrence (tmax) were noted directly from the individual plasma con-
centration versus time profiles. The absolute bioavailability (Fa) of 
venetoclax was calculated according to Eq. 1. All pharmacokinetic pa-
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Mean absorption time (MAT) was calculated from intravenous and 
oral MRT, according equation 2: 
MRTpo = MAT + MRTiv (2) 
Food effect was calculated using the fold difference (FD) in the AUC 







Fold differences (FD) are presented, where possible, as mean FD ±
standard error of the fold difference (SEFD) as calculated by equation 4: 









Where FD is the mean fold difference in food effect, AUCfed and 
AUCfasted are the represent the mean AUC in the fed and fasted states, 
respectively, and SEfed and SEfasted represent the standard errors corre-
sponding to these values, respectively. 
2.7. In silico predictive modelling 
In silico absorption modelling was conducted using GastroPlus™ 
(vers. 9.7, Simulations Plus, Lancaster, Ca.). The ADMET Predictor™ 
module was used to estimate venetoclax physiochemical characteristics. 
Further drug specific data was included in the drug database based on 
published literature (i.e. pKa, experimental permeability values, meta-
bolic pathways, logP, amorphous solubility) (Emami Riedmaier et al., 
2018; FDA, 2015), and are summarized in Table S1 (supplementary 
data). Biorelevant solubility were changed to those measured in vitro. 
The z-factor was established by fitting individual dissolution profiles in 
FaSSIF, FeSSIF and porcine biorelevant media (FaSSIFp) as appropriate 
for the model generated. Pharmacokinetic parameters and bioavail-
ability were fitted to a one-, two- and three-compartment model using 
PKPlus™ module, with goodness of fit assessed using the Akaike Infor-
mation Criterion (AIC) and comparison to previously published ven-
etoclax pharmacokinetic models (Jones et al., 2016). Simulations were 
set to 24 h using the minipig physiology fasted ACAT™ model, and 
incorporated a feeding step at 8 h post dosing. Dose was set to 100 mg 
and dose volume was 50 mL. The minipig physiology fed ACAT™ model 
was modified prior to conducting simulations. Specifically, gastric 
transit time was changed to 5.0 h, based on recently published data 
(Henze et al., 2018a; Henze et al., 2019). Further modifications 
included: adjustment of the food intake, food type was aligned with the 
kcal pigs received during the in vivo studies (FDA style breakfast). 
Gastrointestinal fluid volumes were adjusted to 180 mL in the stomach 
compartment and 120 mL in the small intestinal compartment in the 
fasted and 575 mL and 262 mL in the fed state, based on post-mortem 
collected gastrointestinal content samples (in-house data). All other 
values were kept at default values. Simulated profiles were compared to 
the mean plasma profiles for fasted and fed state conditions. Percent 
prediction errors (% PE) were calculated for each simulation relative to 
the observed data, according to equation 5 (Pathak et al., 2017). 
% PE =
(
predicted mean − observed mean
observed mean
)
∗ 100 (5)  
2.8. Statistical analysis 
The statistical analysis was performed using a paired t-test to 
determine statistical significance (p < 0.05) of calculated in vivo 
bioavailability and pharmacokinetic results. In vitro solubility data were 
tested for significance (p < 0.05) using a two-tailed, independent sample 
t-test, assuming Gaussian distribution and equal variance. All statistical 
analyses were performed using GraphPad Prism version 5. 
3. Results 
3.1. Biorelevant solubility in porcine intestinal media 
The solubility of venetoclax was measured in ex vivo samples of 
porcine intestinal fluids (PIF) and compared to the solubility measured 
in three different biorelevant media, the results of which are summa-
rized in Fig. 1. Biorelevant media representing both the fasted state 
(FaSSIF) and postprandial (FeSSIF) conditions in human intestine were 
used. In addition, a species specific biorelevant media representing the 
fasted intestinal state in landrace pigs (FaSSIFp) was used as predictor of 
in vivo solubility at the absorptive site. 
The solubility of venetoclax measured in FaSSIFp was 154 ± 15 μg/ 
mL, which is higher compared to human FaSSIF (5.2 ± 0.3 μg/mL) and 
can be attributed to the the higher bile salt concentrations in FaSSIFp, 
which is specifically designed to mimic pig intestinal conditions in the 
fasted state (Henze et al., 2020). The solubility in human biorelevant 
media of venetoclax increased from 5.2 ± 0.3 μg/mL in FaSSIF to 28.4 ±
2.2 μg/mL in FeSSIF, reflecting a 5.5 ratio FeSSIF/FaSSIF, which 
correspond to the reported clinical food effect of venetoclax (5- fold 
increase AUCfed/AUCfasted) (Salem et al., 2016). 
The measured solubility of venetoclax in ex vivo pig intestinal fluids 
(PIF) under fasted conditions was 163 ± 82 μg/mL and 299 ± 29 μg/mL 
in the fed state, reflecting a ratio of 1.8 PIFfed/PIFfasted. Therefore, while 
Fig. 1. Solubility of venetoclax in fasted state simulated intestinal fluid (FaS-
SIF), fed state simulated media (FeSSIF), fasted stated simulated porcine in-
testinal fluid (FaSSIFp), porcine intestinal fluids (PIF) in the fasted and in the 
fed state conditions (n=3, mean ± SD). 
Fig. 2. Biorelevant dissolution of venetoclax 100 mg tablets (Venclyxto®) in 
simulated intestinal media, (o) FaSSIF, ([]) FeSSIF, (▴) FaSSIFp. Dotted line 
indicates the reported amorphous solubility of venetoclax in FaSSIF and dashed 
line indicates the reported amorphous solubility of venetoclax in FeSSIF 
(Emami Riedmaier et al., 2018) (n=3, mean ± SD). 
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a trend towards higher solubility was observed in post prandial luminal 
fluids, overall the ratio was lower than the ratio observed in FeSSIF/ 
FaSSIF. Interestingly the solubility of venetoclax in porcine FaSSIFp 
(154 ± 15 μg/mL) closely matched the solubility in ex vivo pig fasted 
intestinal fluids (163 ± 82 μg/mL), which supports the suitability of 
using simulated porcine media to predict luminal drug concentrations. 
3.2. Biorelevant dissolution under simulated fasting and fed state 
conditions 
The dissolution characteristics of venetoclax in porcine biorelevant 
media (FaSSIFp) were compared to the dissolution performance using 
human biorelevant media (FaSSIF & FeSSIF), as presented in Fig. 2. 
The dissolution profile obtained from FaSSIFp, showed a marked 
increase in the extent of dissolution relative to those observed in human 
FaSSIF, with release of 32.1 % after 3 h. Drug release under human 
simulated fasting conditions was low, with approximately 10 % disso-
lution observed after 3 h. This increased to 12.6 % release after 3 h using 
FeSSIF media. The drug release in human biorelevant media was 
compared to the previously reported values of amorphous solubility of 
venetoclax in FaSSIF and FeSSIF, and the drug concentration observed 
after 3 h of dissolution were closely aligned with amorphous solubility of 
the drug (Fig. 2) (Emami Riedmaier et al., 2018). 
3.3. Validation of in silico model with biorelevant in vitro input 
In order to assess the disposition kinetics of venetoclax in pigs, a 
venetoclax formulation containing 25 % Tween 80 in water for injec-
tion, 17 mg of venetoclax was administered intravenously (i.v.). The 
venetoclax plasma concentration time profile obtained after i.v. 
administration is shown in Fig. 3. These data were fitted to one- (AIC =
-6.8863), two- (AIC = -42.7994) and three-compartment (AIC =
-56.674) models. Overall, it was decided to use a two-compartment 
given that the model was found to adequately fit the observed data, 
with limited improvement in using the more complex three- 
compartment model. Furthermore, a two compartment model had 
been successful employed to model previously for pharmacokinetic 
analysis of venetoclax(Jones et al., 2016). The key pharmacokinetic 
parameters are summarised in Table 2. The observed volume of distri-
bution was 0.11 ± 0.02 L/kg, which was marginally lower to values 
reported in humans (0.21 L/kg) (Emami Riedmaier et al., 2018). The 
total clearance of venetoclax in this study was determined to be 0.13 ±
0.02 L/(h*kg). 
The mean plasma concentration profiles obtained after oral admin-
istration of 100 mg Venclyxto® (venetoclax) to fasted pigs are presented 
in Fig. 3. In the fasted state, the median time to reach peak concentra-
tions (tmax) was 12 h (range: 8 – 12 h) due to a secondary peak after 8 h 
post dosing. This secondary absorption phase most likely reflects a post 
prandial phase, as pigs were allowed access to food (after an 8 h fasting 
period post dosing), which resulted in an increased drug absorption at 
this 8- 12 h period. Furthermore, mean absorption time (MAT) was 
affected by this secondary absorption phase, resulting in a longer MAT 
under fasted conditions, ranging from 7.4 to 15.3 h (median 10.0 h), 
compared to the fed state. 
Integration of species specific in vitro methods into in silico models to 
predict in vivo drug levels of venetoclax have been generated by using 
GastroPlus™ software provided by Simulations Plus, Inc., Lancaster, 
California, USA. Modelling of plasma venetoclax concentrations for 
Venclyxto® 100 mg tablets, including in vitro solubilities and dissolution 
kinetics under porcine biorelevant conditions and PKPlus™ fitted 
pharmacokinetic estimates led to an absorption model which accurately 
predicts the observed data in the fasted state. 
The venetoclax plasma profiles were modelled for Venclyxto® 100 
mg tablets, incorporating in vitro solubilites (in PIF and FaSSIFp) and 
dissolution outcomes under biorelevant conditions (in FaSSIFp) and 
PKPlus™ fitted pharmacokinetic estimates using the default mini-pig 
physiological fasted ACAT™ model. Initial model estimates resulted in 
an inadequate prediction of the observed data in the fasted state (Fig. 4 
A). While the default gastric emptying time (GET) in the mini-pig 
physiological fasted ACAT™ model is 0.70 h, corresponding to the 
average time taken for material to pass through the stomach compart-
ment. Based on our previous studies, using paracetamol as a marker for 
gastric emptying the fasted GET in landrace pigs was estimated to be 5.0 
h (Henze et al., 2019). Therefore, a slower gastric emptying rate in 
fasted pigs was incorporated into the model, which resulted in delayed 
absorption phase (Fig. 4 B). Further adjustments of the default mini-pig 
physiological fasted ACAT™ model were deemed necessary to represent 
gastrointestinal conditions in landrace pigs. Based on gastrointestinal 
content samples collected post-mortem luminal fluid volumes were 
adjusted to 180 mL stomach compartment and 120 mL small intestinal 
compartment based on in-house data and published data (Henze et al., 
2019). This resulted in a prediction illustrated in Fig. 4 C, which accu-
rately predicts the initial absorption phase up to 8 h. However, the 
prolonged absorption phase observed in vivo, is not adequately 
modelled, with the result that Cmax is lower in the predicted profile. 
(Cmax predicted 0.23 μg/mL versus Cmax observed 0.36 μg/mL). The 
distinct second peak observed in the fasted plasma concentration pro-
files in vivo occurred at 8 - 12 h, which matches with the time pigs were 
allowed access to food (i.e. 8 h post dosing). This observation is similar 
to previous reports observed for fenofibrate in landrace pigs and is 
suggestive of a post-prandial induced secondary absorption phase, with 
absorption of drug remaining in the gastrointestinal tract occurring in 
response to ingestion of food (O’Shea et al., 2015). This prolonged ab-
sorption phase is not observed in the models used to generate the 
simulated plasma profiles in Fig. 4 A-C. Therefore, a second feeding 
stage at 8 h post dosing was integrated into the physiological fasted 
ACAT™ model (Fig. 4 D). The combination of the prolonged gastric 
Fig. 3. Plasma concentration time profile following intravenous administration 
of 17 mg of venetoclax to landrace pigs (▴); Plasma concentration time profile 
from 0 – 24 h of 100 mg venetoclax in landrace pigs under fasted (o) conditions. 
(mean ± SEM, n= 5). 
Table 2 
Summary of pharmacokinetic parameters following intravenous administration 
of 17 mg of venetoclax and oral administration of 100 mg to fasted pigs (mean ±
SD, n=5).  
IV Pharmacokinetic parameters Oral Pharmacokinetic parameters fasted 
state 
Vc (L/kg) 0.11 ± 0.02 Cmax (μg/mL) 0.43 ± 0.19 
CL (L/(h*kg) 0.13 ± 0.02 tmax (h) a 12.0 (8.0 – 12.0) 
kel (h-1) 1.17 ± 0.17 AUC0-∞ (μg⋅h/mL) 5.5 ±1.2 
k12 (h-1) 1.64 ± 0.32 Fa0-∞ (%) b 12.9 ± 3.7 
k21 (h-1) 0.43 ± 0.11 MAT (h) a 10.0 (7.4 – 15.3) 
AUC0-∞ (μg⋅h/mL) c 0.44 ± 0.05 MRT p.o. (h) a 14.4 (11.0 – 19.6)  
a median (range) 
b F0-∞ = (AUC(oral)0-∞/ AUC(iv)0-∞)*(Dose(iv)/Dose(oral) 
c IV dose corrected 
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transit, the reduction of gastrointestinal fluid volume and the intro-
duction of a modelled feeding step 8 hours post dose appears to improve 
the overall correlation of the simulated and observed plasma profiles. A 
positive correlation was observed between predicted and observed 
plasma concentrations. This model predicted bioavailability in the fas-
ted state to be 11.6 % (% PE -10 %) with a Cmax of 0.33 μg/mL at 11 h 
(% PE – 6 %). 
3.4. Applying an integrated in vitro- in silico approach to predict a food 
effect of venetoclax in pigs 
The mean plasma concentration profiles obtained after oral admin-
istration of 100 mg Venclyxto® (venetoclax) to fed pigs are presented in 
Fig. 5. The main pharmacokinetic parameters are summarized in 
Table 3. 
In the fed state the absorption of venetoclax was significantly higher 
compared to the fasted state. AUC0-∞ increased from 5.5 ± 1.2 μg⋅h/mL 
in the fasted state to 12.5 ± 3.2 μg⋅h/mL in the fed state. The absolute 
bioavailability of 28.7 ± 7.5 % in the fed state compared to 12.9 ± 3.7 % 
in the fasted state, reflecting a 2.3 ± 0.5-fold increase (p<0.05) after 
administration of the FDA style high-fat, high-caloric breakfast. Looking 
at the 0- 8 h post dose period (i.e. AUC0-8h) indicated an even more 
pronounced 8.4 ± 4.0-fold increase in bioavailability between fed and 
fasted state conditions. 
The combination of species specific in vitro and in silico methods to 
predict in vivo drug levels in the fed state have been used to assess the 
potential impact of food on the bioavailability of venetoclax. Modelling 
Fig. 4. GastroPlus™ in silico model of plasma venetoclax concentration vs time profile compared to observed in vivo pig data, line indicates the predicted data, (o) 
indicates the observed data (n= 5, mean ± SEM); A: standard mini-pig physiological fasted ACAT™ model; B: mini-pig physiological fasted ACAT™ model with a 
delayed gastric emptying (5.0 h); C: landrace specific model with a delayed gastric emptying and gastrointestinal volumes adjustment; D: landrace specific model 
with a delayed gastric emptying, gastrointestinal volumes adjustment and a incorporated feeding step at 8 h post dosing. 
Fig. 5. GastroPlus™ in silico model of plasma venetoclax concentration vs time 
profile compared to observed in vivo pig data, solid line indicated the predicted 
fed state profile, (▴) indicated the observed data (n=5, mean ± SEM). 
Table 3 
Pharmacokinetic parameters of venetoclax after oral administration of 100 mg 
per animal under postprandial conditions (mean ±SD, n=5).  
Pharmacokinetic parameters  
Fed observed Fed predicted 
Cmax (μg/mL) 1.24 ± 0.29 1.11 
tmax (h) a 6.0 (4.0 – 8.0) 6.4 
AUC0-∞ (μg⋅h/mL) 12.5 ± 3.2 c 9.53 
Fa0-∞ (%) b 28.7 ± 7.5 c 22.2 
Food effect 0-∞ d 2.3 ± 0.5, (1.79 – 3.20) 1.86  
a median (range) 
b F0-∞ = (AUC(oral)0-∞/ AUC(iv)0-∞)*(Dose(iv)/Dose(oral) 
c significant difference to the fasted equivalent parameter (p < 0.05) 
d calculated according to equation 3, reported as mean values of the indi-
vidual fed/fasted ratios 
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of plasma venetoclax concentrations for Venclyxto® 100 mg tablets, 
included luminal solubility of venetoclax under fasted and fed state 
condition (PIFfasted & PIFfed) and dissolution kinetics under porcine 
biorelevant conditions (FaSSIFp), which lead to an absorption model 
which accurately predicts the observed in vivo drug levels in the post-
prandial state. 
The porcine in silico model predicted a 22 % increase in oral 
bioavailability in the fed state, and an overall predicted food effect of 
1.86 was predicted, which compared well with the range of values found 
in vivo (1.79 – 3.20). The in silico predictions are therefore in line with 
observations in vivo for absolute bioavailability in the fed state (% PE -23 
%). Furthermore, the predicted Cmax of 1.11 μg/mL at 6.4 h compares to 
Cmax 1.18 μg/mL at 7.0 h in vivo (% PE -10 %). 
A crucial input parameter for this model, mimicking the postprandial 
absorption of venetoclax, was the solubility measured in pig intestinal 
fluid samples under fasted and fed conditions (PIF), which was com-
bined with the dissolution kinetics obtained using FaSSIFp. A sensitivity 
analysis was conducted using three-dimensional surface response plots, 
examining the effect of intestinal solubility (based on the bile salt sol-
ubilisation ratio), as well as dissolution kinetics (based on the dissolu-
tion parameter, z- factor) on simulated plasma profiles. The increase of 
intestinal solubility/ bile salt solubilisation ratio leads to an increase in 
absorption, in comparison the effect of the z- factor as input parameter 
was less significant (supplementary data, Fig. S1). 
4. Discussion 
During drug development there is a clear need for preclinical species 
specific in vitro and in silico tools to provide early forecasts of drug 
formulation performance in vivo. Therefore, improvements of in vitro- in 
silico models to predict in vivo absorption will address dual goals of (i) 
developing optimal formulation strategies to improve drug absorption, 
and (ii) predicting impact of food on oral drug product performance 
early in the product lifecycle. Developing biopharmaceutics tools that 
link formulation design to overcome solubility limitation and reduce 
food effect are key to avoid costly re-formulation in later stage of clin-
ical/ commercial development. Accordingly, integrating species specific 
in vitro tools with in silico models provide for more informed decision 
making on the formulation properties and possible food effects in a 
preclinical setting. 
As a BCS class IV drug, venetoclax displays poor solubility and 
permeability. This class of drugs typically exhibit dissolution or solu-
bility limited absorption (Emami Riedmaier et al., 2018). Therefore, an 
estimation of drug solubility in the gastrointestinal tract is considered 
critical to better understand limitations of their absorption. In this study, 
solubility of venetoclax was measured in three different biorelevant 
media (FaSSIFp, FaSSIF and FeSSIF) and compared to solubility values 
obtained in ex vivo porcine intestinal fluids (PIF). The comparisons 
revealed that using human biorelevant media to estimate in vivo solu-
bility in pigs does not appear adequately predictive. The solubilities 
measured in FaSSIF (5.2 ± 0.1 μg/mL) under predicted the solubility in 
PIFFasted (163 ± 82 μg/mL), showing a 30-fold lower solubility. Solu-
bility in FaSSIFp (154 ± 15 μg/mL) was similar to the obtained solubility 
in PIFFasted and therefore supports the use of this simulated media in 
estimating luminal solubility in pigs in the fasted state. As there is 
currently no available biorelevant medium simulating PIFFed, ex vivo 
Fig. 6. GastroPlus™ simulations- in silico model of plasma venetoclax concentration vs time profile compared to observed in vivo pig data, A: solid line indicated the 
predicted fasted profile, based on in vitro FaSSIF data; B: solid line indicated the predicted fasted profile, based on in vitro FaSSIFp data (reproduced from Fig. 4D); C: 
solid line indicated the predicted fed profile, based on in vitro FeSSIF data; D: solid line indicated the predicted fed profile, based on in vitro FaSSIFp and PIFfed data 
(reproduced from Fig. 5; (o) indicates the observed fasted state data, (▴) indicated the observed fed state data (n=5, mean ±SEM). 
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measurements of venetoclax solubility in PIFFed were used to estimate in 
vivo intestinal solubility in the fed state pigs. An increase in solubility 
using fed state media was observed (ratio of 5.5 FeSSIF/FaSSIF; 1.8 
PIFfed/PIFfasted), which is in line with clinical observation for venetoclax 
when co-administered with food, reflecting a 4.5 ± 3.2-fold increase of 
AUC after a high fat meal (753 kcal) and 3.1 ± 2.3–fold increase of AUC 
after a low fat meal (512 kcal) in contrast to fasted state conditions 
(Salem et al., 2016). 
To date, most of the published studies with PBPK models in pre-
clinical species either utilize human biorelevant media or attempt ex-
trapolations from the human biorelevant media to preclinical species 
based on the expected changes in bile micelle concentrations (Lignet 
et al., 2016; Suenderhauf and Parrott, 2013). Therefore, one of the 
primary aims of this study was to assess the capability of porcine specific 
simulated intestinal fluids to mimic luminal drug concentrations in 
combination with a porcine in silico model to forecast plasma concen-
trations in vivo. Accurate simulation of animal studies requires the 
appropriate solubility input, and this study demonstrated the merits of a 
species specific biorelevant in vitro testing for providing more accurate 
prediction in vivo (Fig. 6). The use of solubility estimates from human 
biorelevant media (FaSSIF and FeSSIF) as inputs to the specific landrace 
pig in silico model, incorporating physiological data for gastric emptying 
and gastrointestinal fluid volumes in landrace pigs reported by Henze 
et al. (2019), resulted in a poor correlation with porcine in vivo data, in 
both the fasted and fed state (Fig. 6 A and Fig. 6 C). By using human 
FaSSIF to predict plasma concentrations in pigs clearly under-predicted 
the observed drug plasma concentration for venetoclax (predicted 
AUC0-∞ 2.9 μg*h/mL compared to observed AUC0-∞ 5.5 μg*h/mL (% PE 
-50)). However, the use of porcine specific in vitro data measured in 
FaSSIFp, improved the predictions (Fig. 6 A versus Fig. 6 B) and confirm 
the importance of using appropriate input parameters to model pre-
clinical conditions (Fig. 6 B and D). 
For predicting fed state conditions, solubility from ex vivo PIFfed, 
combined with dissolution kinetics obtained from FaSSIFp, successfully 
predicted the food induced increase in absorption of venetoclax. This 
reaffirms the importance of using biorelevant input parameters, as pa-
rameters based on human biorelevant media under predicted the 
observed fold increase of venetoclax in vivo (Fig. 6 C). This approach of 
using an integrated porcine PBPK model therefore offers a novel 
approach of mechanistically capturing the food effect of bioenabling 
formulations in a preclinical setting. While availability of ex vivo PIFfed 
to estimate luminal solubility in the fed state, as employed here, has 
limitations for more widespread applications as a preclinical tool, ap-
proaches to establish a media for simulating fed state conditions in pigs 
are therefore merited going forward. 
Our findings are similar to those studies reported for dogs, where 
Walsh and co-workers reported improved predictions of plasma con-
centration profiles in dogs, when using data obtained in canine fasted 
simulated intestinal fluid. In their study in vitro results indicated that 
canine biorelevant media resulted in a 40-fold higher solubility of the 
investigational drug (‘compound free acid 6’) relative to human FaSSIF, 
which led to significant under-prediction of exposures for the drug when 
using human FaSSIF as an input parameter(Jones et al., 2006; Walsh 
et al., 2017). Given that both dogs and pigs are widely used in preclinical 
screening, it is important to establish species related differences in drug 
solubility and dissolution characteristics, and the usage of specific bio-
relevant in vitro tools provide a useful approach of addressing this need. 
This may further provide a useful tool in guiding the selection of an 
appropriate preclinical model and also offering the advantages of 
reducing repeated in vivo testing in different animal models. 
The present mechanistic PBPK models have shown success in pro-
spectively simulating absorption of venetoclax in pigs. It must be noted 
that species specific gastrointestinal transit times need to be accounted 
when simulating intestinal absorption, the default minipig ACAT model 
includes a gastric transit time of 0.70 h. However, based on recent 
studies (Henze et al., 2018a; Henze et al., 2020; Suenderhauf et al., 
2014), gastric emptying is prolonged in pigs, and adjustment to more 
appropriate estimates can improve the in silico model significantly. This 
is in line with the findings from Suenderhauf and co-workers, the 
established PBPK model for Göttingen minipigs was refined by using 
prolonged gastric emptying rate, which lead to more accurate PK pre-
dictions of the model compounds (Suenderhauf and Parrott, 2013). The 
adjusted minipig ACAT™ model used in this study further incorporated 
pig specific gastrointestinal adjustments and resulted in improved cor-
relation to in vivo data, capturing the observed plasma concentration of 
venetoclax in fasted pigs (Fig. 4 D). 
This study further demonstrated the utility of the pig model to pre-
dict the food effects of poorly water soluble drugs in humans. A signif-
icant increase in absolute bioavailability of 28.7 ± 7.5 % in the fed state 
compared to 12.9 ± 3.7 % in the fasted state, reflecting a 2.3 ± 0.5-fold 
increase (p< 0.05), showed that venetoclax absorption is a higher under 
postprandial conditions in pigs. The observed increase in bioavailability 
of venetoclax in landrace pigs was in line with observation from clinical 
food effect studies, where the reported food effect of venetoclax in 
humans was approximately 3.1 ± 2.3 –fold higher after a low fat meal 
(512 kcal) and 4.5 ± 3.2-fold after a high fat meal (753 kcal) (Salem 
et al., 2016). Previously we have established a food effect protocol in 
landrace pigs, and demonstrated, using fenofibrate, a significant 2-fold 
higher bioavailability in the fed state over the 0- 8 h post dosing 
period (Henze et al., 2019). This observation was in line with food effect 
previously reported for fenofibrate in humans. Applying the same 
porcine food effect protocol for venetoclax, similarly demonstrated a 
significantly increased bioavailability after administration with the FDA 
style high fat breakfast to pigs, with an 8.4-fold higher AUCfed/AUCfasted 
ratio over the 0- 8 h post dosing period. Similar to our previous study, a 
distinct secondary absorption phase was observed on feeding the pigs 
after 8 h, and while this reduced the overall AUCfed/AUCfasted ratio to 2.3 
± 0.5, overall the statistical significance was maintained over the 
complete period of 0- ∞ h. 
5. Conclusion 
In summary, an important aim of this work was to capture the ven-
etoclax plasma concentration profile under fasted and fed conditions in 
pigs, by accurately incorporating biorelevant solubility and biorelevant 
dissolution using a novel pig biorelevant medium. The optimized pig 
ACAT model was able to mechanistically capture the disposition of 
venetoclax in pigs, while accounting for species specific dissolution and 
solubility inputs. This study showed that the applied porcine physio-
logically based absorption model was able to prospectively simulate the 
in vivo behaviour of venetoclax in landrace pigs, by combining porcine 
biorelevant in vitro and in silico tools. Using in vitro solubility and 
dissolution data for venetoclax measured in species specific simulated 
fluids (FaSSIFp), correctly predict the observed in vivo drug levels of 
venetoclax in fasted pigs. In addition, by combining porcine luminal 
solubility and porcine biorelevant dissolution data with in silico 
modelling, accurately predicted the observed preclinical food effect in 
vivo. The study further confirmed that the utility of the landrace pig 
model for predicting food effect in humans, and in this case for a BCS 
class IV compound. Overall the findings demonstrate the merits of 
integrating physiologically-informed in vitro and in silico tools for pre-
dicting drug product performance in a preclinical setting, and advance 
the use of these approaches for optimising clinical drug product design 
at an earlier stage in development. 
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